

Clinical trials of aloglitazar

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
aloglitazar vs actos			
BC20265 <i>ongoing</i> [NCT00461058] n=NA follow-up:	aloglitazar versus Actos(r)	-	USA
aloglitazar vs placebo			
ALECARDIO [NCT01042769] n=NA	-	-	
ALEPREVENT [EUDRACT201200067116] n=1999 follow-up: 58 days	aloglitazar 150 g versus placebo	patients with T2D or prediabetes with established, stable CV disease	Parallel groups double-blind
ALECARDIO , 2014 [NCT01042769] n=3616/3610 follow-up: 2 years (median)	aloglitazar 150 g daily versus placebo	patients hospitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes	Parallel groups double-blind
BC22140 <i>ongoing</i> [NCT01042769] n=NA follow-up: 2.5 years	aloglitazar on top of standard care versus placebo	patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus	double-blind USA

More details and results :

- insulin sensitizer for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q377>
- insulin sensitizers - PPAR modulator for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q552>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at <http://www.trialresultscenter.org/go-Q692>

References

BC20265, 0:

ongoing trial NCT00461058

ALECARDIO, :

ALEPREVENT, :

Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. Am Heart J 2015;170:117-22 [[26093872](#)]

ALECARDIO, 2014:

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydn L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014 Apr 16;311:1515-25 [[24682069](#)] [10.1001/jama.2014.3321](#)

BC22140, 0:

ongoing trial NCT01042769